OncoMatch/Clinical Trials/NCT06566079
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors
Is NCT06566079 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies ISM6331 for malignant mesothelioma.
Treatment: ISM6331 — This is a Phase 1, open-label, multicenter, FIH study to evaluate the safety, tolerability, recommended Phase 2 dose (RP2D), PK/PD, and preliminary anti-tumor activity of ISM6331 in participants with advanced or metastatic malignant mesothelioma or other solid tumors. The study consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Mesothelioma
Tumor Agnostic
Disease stage
Required: Stage IV
Metastatic disease required
unresectable advanced or metastatic malignant mesothelioma or other solid tumors
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: immune checkpoint therapy
Participants with malignant mesothelioma must have prior exposure to at least immune checkpoint therapy
Must have received: platinum-based chemotherapy
Participants with malignant mesothelioma must have prior exposure to at least...platinum-based chemotherapy
Cannot have received: TEAD inhibitor
Participants who have previously received a TEAD inhibitor
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Sarah Cannon Research Institute at HealthONE · Denver, Colorado
- The University of Chicago Medical Center - Duchossois Center for Advanced Medicine · Chicago, Illinois
- University Hospitals Cleveland Medical Center · Cleveland, Ohio
- University of Pennsylvania - Abramson Cancer Center · Philadelphia, Pennsylvania
- SCRI Oncology Partners · Nashville, Tennessee
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06566079 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior TEAD inhibitor disqualifies patients from enrollment.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages